Business Description
Athira Pharma Inc
NAICS : 541714
SIC : 2833
ISIN : US04746L1044
Share Class Description:
ATHA: Ordinary SharesDescription
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.83 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -18.9 | |||||
| 3-Year EPS without NRI Growth Rate | -17.4 | |||||
| 3-Year FCF Growth Rate | -27.8 | |||||
| 3-Year Book Growth Rate | -48.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 54.23 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.96 | |||||
| 9-Day RSI | 46.53 | |||||
| 14-Day RSI | 48.77 | |||||
| 3-1 Month Momentum % | 15.74 | |||||
| 6-1 Month Momentum % | -46.74 | |||||
| 12-1 Month Momentum % | -87.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.26 | |||||
| Quick Ratio | 7.26 | |||||
| Cash Ratio | 6.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | 3.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -120.89 | |||||
| ROA % | -92.03 | |||||
| ROIC % | -1080.12 | |||||
| 3-Year ROIIC % | 62.95 | |||||
| ROC (Joel Greenblatt) % | -2214.39 | |||||
| ROCE % | -117.57 | |||||
| Moat score | 5 | |||||
| Tariff score | 9 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.31 | |||||
| Price-to-Tangible-Book | 0.31 | |||||
| EV-to-EBIT | 0.3 | |||||
| EV-to-EBITDA | 0.31 | |||||
| EV-to-FCF | 0.28 | |||||
| Price-to-Net-Current-Asset-Value | 0.35 | |||||
| Price-to-Net-Cash | 0.39 | |||||
| Earnings Yield (Greenblatt) % | 333.33 | |||||
| FCF Yield % | -732.23 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers